About Us | Contact Us | Editorial Board | About Haymarket Media

RSS | Login | Register

The more we know about our visitors, the easier it will be for us to publish everything you want to see.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Vinblastine injection

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare Vinblastine injection to:

Generic Name for Vinblastine injection

Vinblastine (as sulfate) 1mg/mL; soln for IV inj or infusion; contains benzyl alcohol.

Legal Classification:

Pharmacological Class for Vinblastine injection

Antimicrotubule agent.

Manufacturer of Vinblastine injection

Abraxis Oncology

Indications for Vinblastine injection

Less frequently responsive: choriocarcinoma resistant to other chemotherapy.

Other Indications for Vinblastine injection

Breast cancer

Kaposi's sarcoma

Leukemias, lymphomas, and other hematologic cancers

Prostate and other male cancers

Adult dose for Vinblastine injection

See literature. Give by IV once weekly. 1^st dose: 3.7mg/m² as a single dose, continue to increase dose by increments (2^nd dose: 5.5mg/m², 3^rd dose: 7.4mg/m², 4^th dose: 9.25mg/m², 5^th dose: 11.1mg/m², max dose: 18.5mg/m²) until WBC 3,000cells/mm³ reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m². Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm³. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children's dosing for Vinblastine injection

Not recommended.

Also:

Vinblastine for injection

Contraindications for Vinblastine injection

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions for Vinblastine injection

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions for Vinblastine injection

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

Adverse Reactions for Vinblastine injection

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How is Vinblastine injection supplied?

Pwd—10
Soln—1

Related Disease:

Cancer, breast

Cancer, placenta

Cancer, testicular

Hodgkin's disease

Kaposi's sarcoma

Letterer-Siwe disease

Lymphoma, histiocytic

Lymphoma, lymphocytic

Mycosis fungoides~antineoplastics

Data provided by the Monthly Prescribing Reference (MPR) Hematology/Oncology Edition.

Adjuvant Radiochemotherapy Has Lasting Benefit in Gastric Cancer

May 18, 2012

Patients with gastric cancer who undergo resection show survival benefit 10 years later.

Fertility-Related Information Urgently Needed for Female Patients with Cancer

Debra Hughes May 18, 2012

Young adult males and females with cancer receive vastly different amounts of fertility-related and fertility preservation information.

STAT3 Mutations ID'd in Rare Lymphoproliferative Disorder

May 18, 2012

Four specific mutations in SH2 domain seen in T-cell large granular lymphocytic leukemia.

Genetic Profiling Improves Prognosis of Uveal Melanoma

James Netterwald, PhD May 18, 2012

Gene expression profiling (GEP) and chromosomal analysis show prognostic value in patients with uveal melanoma.

Bisphosphonates Cut Skeletal Morbidity in Multiple Myeloma

May 18, 2012

Zoledronate superior to placebo or etidronate for improving overall survival.

CAMPATH

Oncology > Leukemias, lymphomas, and other hematologic cancers

Alemtuzumab 30mg/mL; soln; for IV infusion after dilution; preservative-free.

COSMEGEN

Oncology > Prostate and other male cancers

Dactinomycin 500mcg/vial; lyophilized pwd for IV inj or regional perfusion after reconstitution; contains mannitol; preservative-free.

Fluorouracil

Oncology > Breast cancer

Fluorouracil 50mg/mL; soln for IV inj.

MATULANE

Oncology > Leukemias, lymphomas, and other hematologic cancers

Procarbazine (as HCl) 50mg; caps.

TAXOL

Oncology > Kaposi's sarcoma

Paclitaxel 6mg/mL; soln for IV infusion after dilution; contains Cremophor EL (polyoxyethylated castor oil), dehydrated alcohol.

Oncology > Cytoprotective and supportive care agents

Bisphosphonates (eg, Aredia, Zometa) may inhibit the activation of cancer-associated proteins through the suppression of geranyl-geranylation and farnesylation or inhibit ...
more »

'Teachable Moments' for Smoking Cessation in Patients Diagnosed with Cancer Underutilized

Debra Hughes February 16, 2012

Less than one-fifth (18.1%) of healthcare providers reported high levels of confidence in their ability to counsel patients with cancer who smoke to quit smoking, a survey published in The Oncologist online February 14 has found.